News

In April, BioLineRx began phase I clinical trials to evaluate the safety and determine the pharmacokinetic profile of the compound, BL-1020, in humans. “We continue to be very

The trial, which will enroll 3400 patients with a history of recent heart attack, will focus on African-American heart patients who carry an at-risk variant of one of

Azilect was approved in Europe and Israel in 2005, where it has been successfully launched. In the EU, it is now marketed in 13 countries in collaboration with

The dose-escalating phase I study will determine if Seneca valley virus (SVV-001) can be systemically administered safely to patients with certain types of advanced neuroendocrine cancers, including small

The novel oral formulation provides rapid absorption of apomorphine directly into the bloodstream after sublingual (under the tongue) administration. This novel formulation would offer patients an improved alternative

The study, expected to enroll approximately 50 patients, will evaluate the safety, tolerability and pharmacokinetics of escalating single and multiple doses of VX-770 in healthy volunteers, and also

According to Pfizer, the approval makes Aromasin the first and only aromatase inhibitor approved in Canada for the indication. Results from the study that supported this approval showed

The selection of the candidate by Pfizer constitutes a milestone in the collaboration between the two companies which will result in Rigel receiving a $5 million payment. The

The new data show Rasilez provides significant blood pressure reductions, sustained over 24 hours. Meanwhile, new data on Exforge show that its dual mechanism of action lowered systolic